CARBYLAN THERAPEUTICS INC

Inactive Instrument

Analyst Reco. Carbylan Therapeutics Inc Nasdaq

Equities

US1413841073

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Kalvista Pharmaceuticals Insider Sold Shares Worth $258,337, According to a Recent SEC Filing	05-21	MT
HC Wainwright Adjusts Price Target on KalVista Pharmaceuticals to $24 From $16, Maintains Buy Rating	02-14	MT
SVB Securities Adjusts KalVista Pharmaceuticals' Price Target to $20 From $30, Maintains Outperform Rating	23-02-03	MT
HC Wainwright Adjusts KalVista Pharmaceuticals' Price Target to $16 From $48, Reiterates Buy Rating	22-10-06	MT
SVB Securities Adjusts Price Target on KalVista Pharmaceuticals to $30 From $45, Keeps Outperform Rating	22-10-05	MT
Needham Lowers KalVista Pharmaceuticals Price Target to $24 From $38, Maintains Buy Rating	22-10-04	MT
SVB Securities Adjusts KalVista Pharmaceuticals' Price Target to $45 from $51, Keeps Outperform Rating	22-07-08	MT
Needham Adjusts Price Target on KalVista Pharmaceuticals to $38 From $42, Reiterates Buy Rating	22-07-08	MT
Stifel Nicolaus Adjusts KalVista Pharmaceuticals' Price Target to $32 From $54, Maintains Buy Rating	22-06-08	MT
Needham Adjusts KalVista Pharmaceuticals' Price Target to $42 from $48, Keeps Buy Rating	22-03-11	MT
Cantor Fitzgerald Lowers Price Target for KalVista Pharmaceuticals to $33 From $49, Maintains Overweight Rating	22-03-10	MT
Needham Adjusts KalVista Pharmaceuticals' Price Target to $48 from $50, Keeps Buy Rating	21-12-10	MT
KALVISTA PHARMACEUTICALS : Roth Capital Adjusts Price Target on KalVista Pharmaceuticals to $55 From $30, Maintains Buy Rating	21-02-18	MT
KALVISTA PHARMACEUTICALS : SVB Leerink Adjusts Price Target on KalVista Pharmaceuticals to $51 From $39, Keeps Outperform Rating	21-02-10	MT
KALVISTA PHARMACEUTICALS : HC Wainwright Adjusts Price Target on KalVista Pharmaceuticals to $48 From $30, Maintains Buy Rating	21-02-10	MT
KALVISTA PHARMACEUTICALS : Stifel Adjusts Price Target on KalVista Pharmaceuticals to $54 From $30, Reiterates Buy Rating	21-02-09	MT
KALVISTA PHARMACEUTICALS : Needham Adjusts KalVista Pharmaceuticals' Price Target to $32 From $25, Keeps at Buy	21-01-26	MT
KALVISTA PHARMACEUTICALS : SVB Leerink Adjusts KalVista Pharmaceuticals' Price Target to $39 From $28, Keeps at Outperform	20-11-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer